New report: Prevalence of CKD in the U.S. projected to increase 16.7% by 2030

RTI InternationalMar 3 2015

The prevalence of chronic kidney disease (CKD) will rise in the United States, according to a new report led by RTI International and published in the American Journal of Kidney Diseases during March's National Kidney Month.

According to researchers, the number of adults aged 30 or older who have CKD is projected to increase from 13.2 percent currently, to 14.4 percent in 2020 and 16.7 percent in 2030.

The prevalence model, developed by RTI for the United States Centers for Disease Control and Prevention, illustrates some of issues the nation will face as diabetes rates increase and Americans live longer.

"We were surprised by the high probability of developing CKD during a lifetime," said Thomas Hoerger, Ph.D., a health economist and senior fellow at RTI and the paper's lead author. "It's higher than most diseases that immediately jump to mind, and while the likelihood of chronic kidney disease progressing to complete kidney failure is much lower, CKD itself has been linked to a number of comorbidities and adverse health outcomes."

For U.S. adults aged 30 to 49, 50 to 64, and 65 or older with no CKD at baseline, the residual lifetime incidence of CKD is 54 percent, 52 percent, and 42 percent, respectively, according to the research. This compares to lifetime incidences of 12.5 percent for breast cancer in women, 33 percent to 38 percent for diabetes, and 90 percent for hypertension in middle-aged men and women.

"People need to be aware that as we age beyond 50 years, we lose kidney function, making age over 60 a risk condition for CKD," said Joseph Vassalotti, MD, Chief Medical Officer for the National Kidney Foundation. "CKD progression can be slowed with lifestyle changes and medications. That is why National Kidney Foundation advocates for annual kidney screenings among people most at risk - those with high blood pressure, diabetes, a family history of kidney failure and those over age 60."

The health impact of the projected rise in CKD will be felt not only by individuals, but by the U.S. healthcare system. Medicare expenditures for kidney disease and kidney failure were already over $87 billion in 2012 according to analysis conducted by the U.S. Renal Data System.

"Hopefully this model will help policy makers become aware of chronic kidney disease as a growing problem that needs to be addressed," Hoerger said. "Ideally this will act as an impetus to invest in interventions and discoveries that can slow the progression of kidney disease."

Researchers at RTI International will continue to further refine their model to incorporate other national health issues, such as obesity, and to also assess how positive interventions could alter the course of kidney disease in America.